The oral drug by Merck & Co. smashes all competitors for the treatment and prevention of atherosclerosis.
AFFiRiS
Posted inClinical Trials, In the Pipeline, Neuroscience
Treating Parkinson’s Disease: Betting on Alpha-Synuclein
The pharmaceutical industry continues to fight hard against the devastating neurodegenerative disease.